B. Riley analyst Anderson Schock initiated coverage of Nutex Health with a Buy rating and $290 price target. Nutex Health operates a network of micro-hospitals serving the gap between urgent care and large ERs, with an out-of-network arbitration-driven model and a new capital-light expansion strategy using sale-leasebacks to fund 3-5 annual openings, the analyst tells investors in a research note. While 2026 results are expected to reset lower due to non-recurring arbitration benefits, improving reimbursement efficiency and referral networks support a constructive long-term growth outlook, the firm says.
